UF Health Pathology Laboratories' Hematopathology Division provides comprehensive diagnostic testing for hematologic malignancies using state-of-the-art technology. Our medical staff is composed of expert pathologists and technical scientists who are available to give you personalized service.
- Comprehensive leukemia myelodysplasia or cytopenia evaluation
- Comprehensive lymphoma/lymphoproliferative evaluation
- Comprehensive plasma cell disorder evaluation
- Disease monitoring
- Consultation on pathologic materials (slides)
- Conventional Microscopy: Bone marrow examination is critical for the care of patients with a wide variety of hematopoietic diseases. The presence of immature or morphologically atypical cells in the peripheral blood (an unexplained deficiency or excess of peripheral blood leukocytes or platelets), splenomegaly and unexplained anemia are common indications to obtain bone marrow specimens for diagnosis.
- Immunohistochemistry: This is a staining method that uses antibodies to identify and mark antigens expressed by cells in tissues. When histopathology alone proves inconclusive, immunohistochemistry can help determine diagnosis.
- Flow Cytometry: Now a standard and routine practice for the evaluation of lymphomas and leukemia, flow cytometry is considered to be second only to morphology for a diagnosis of hematolymphoid neoplasms. DNA ploidy and S-phase analysis by flow cytometry may be used as a tool in determining prognosis for patients with lymphoma.
- Molecular Genetic Testing: This test classification can provide sensitive and specific detection of neoplastic changes associated with malignancies, such as chronic myelogenous leukemia, promyelocytic leukemia, follicular lymphoma and many other hematolymphoid neoplasms. We offer a complete and extensive test list of molecular genetic tests.
- Cytogenetics: Performing chromosome analysis for hematological disorders of bone marrow can help to identify specific chromosome rearrangements. These rearrangements in neoplastic cells are often correlated to specific types of leukemia or myelodysplasia. This information aids clinicians in making accurate diagnoses, predicting prognoses and guiding treatment.
- Fluorescence In-Situ Hybridization (FISH): This test is the application of fluorescently labeled DNA molecules to metaphase chromosomes and interphase nuclei for the detection of chromosome abnormalities and alterations. It is a rapid, reliable and direct approach for diagnosis, prognosis and management of hematologic malignancies.